Harry W. Alcorn Jr., Pharm.D.
Net Worth

Last updated:

What is Harry W. Alcorn Jr., Pharm.D. net worth?

The estimated net worth of Dr. Harry W. Alcorn Jr., Pharm.D. is at least $2,998,411 as of 15 Sep 2021. He owns shares worth $268,901 as insider and has received compensation worth at least $2,729,510 in DiaMedica Therapeutics Inc..

What is the salary of Harry W. Alcorn Jr., Pharm.D.?

Dr. Harry W. Alcorn Jr., Pharm.D. salary is $389,930 per year as Senior Vice President of Clinical Operations in DiaMedica Therapeutics Inc..

How old is Harry W. Alcorn Jr., Pharm.D.?

Dr. Harry W. Alcorn Jr., Pharm.D. is 69 years old, born in 1956.

What stocks does Harry W. Alcorn Jr., Pharm.D. currently own?

As insider, Dr. Harry W. Alcorn Jr., Pharm.D. owns shares in one company:

Company Title Shares Price per share Total value
DiaMedica Therapeutics Inc. (DMAC) Senior Vice President of Clinical Operations 43,582 $6.17 $268,901

What does DiaMedica Therapeutics Inc. do?

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DMAC logo
DMAC
DiaMedica Therapeutics Inc.
$6.17

Harry W. Alcorn Jr., Pharm.D. insider trading

DiaMedica Therapeutics Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Voting Common Shares, no par value per share 15,000 $3.8 $56,955
Purchase
Voting Common Shares, no par value per share 20,721 $3.07 $63,696
Purchase
Voting Common Shares, no par value per share 7,260 $2.67 $19,362
Purchase
Voting Common Shares, no par value per share 150 N/A N/A
Purchase
Voting Common Shares, no par value per share 1,000 $4 $4,000

DiaMedica Therapeutics key executives

DiaMedica Therapeutics Inc. executives and other stock owners filed with the SEC:

  • Dr. Harry W. Alcorn Jr., Pharm.D. (69) Senior Vice President of Clinical Operations
  • Mr. Dietrich John Pauls MBA (54) Pres, Chief Executive Officer & Director
  • Mr. Scott B. Kellen C.A. (60) Chief Financial Officer & Company Sec.